Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
What is your approach to addressing severe dawn phenomenon in your patients with diabetes?
Related Questions
Do you avoid empagliflozin in patients with history of amputation?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
Outside of teplizumab, what therapies do you recommend for preserving beta cell function in patients with early stage type 1 diabetes mellitus?
Is there a role for intermittent fasting as part of the management of a patient with long-standing type 2 diabetes and consistently poor glycemic control despite maximal therapy?
What is the clinical importance of differentiating between impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) states?
When do you recommend screening patients with T2DM for heart failure?
What is the typical timeline for remission of autoimmune hypoglycemia?
Which patients would benefit most from teplizumab therapy to delay the onset of T1DM?
When should metformin be stopped before surgery and when is it considered safe to resume?
Do you routinely monitor INR when starting GLP1 R agonist therapy on patients taking warfarin?
